Advertisement

Breast Cancer Research and Treatment

, Volume 169, Issue 2, pp 391–396 | Cite as

Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience

  • Nicholas B. Figura
  • Wendy Long
  • Michael Yu
  • Timothy J. Robinson
  • Sepideh Mokhtari
  • Arnold B. Etame
  • Nam D. Tran
  • Roberto Diaz
  • Hatem Soliman
  • Heather S. Han
  • Solmaz Sahebjam
  • Peter A. Forsyth
  • Kamran A. Ahmed
Brief Report

Abstract

Purpose

Leptomeningeal disease is a rare and devastating presentation of advanced stage metastatic breast cancer with historically poor overall survival. We assessed the safety and feasibility of intrathecal (IT) trastuzumab in HER2+ leptomeningeal disease.

Methods

A total of 13 patients were treated at our institution with IT trastuzumab beginning November 2012 and followed until November 2017. Outcomes including craniospinal progression as well as overall survival (OS) following initiation of IT trastuzumab were assessed from review of the clinical chart and radiologic examinations.

Results

The median age of patients was 48 (range 29–75). Median time from breast cancer diagnosis to development of brain metastases was 87.7 months with a median of 4.6 months from brain metastases diagnosis to the development of leptomeningeal disease. Previous whole brain radiotherapy was received by the majority of patients (92%) and prior surgery for brain metastases was performed in 23%. Median duration of IT trastuzumab treatment was 6.4 months. Median time from IT trastuzumab start to craniospinal progression was 5.7 months with 6- and 12-month Kaplan–Meier rates of 41 and 21%, respectively. Sustained responses > 6 months were achieved in 4 patients. Median survival from the start of IT trastuzumab was 10.6 months with 6- and 12-month OS rates of 68 and 47%, respectively. IT trastuzumab was well tolerated with one patient developing ventriculitis, which resolved with IV antibiotics.

Conclusions

IT trastuzumab was well tolerated with prolongation of OS over historical controls. IT trastuzumab should be considered for management of HER2+ leptomeningeal disease patients.

Keywords

Intrathecal trastuzumab Intrathecal herceptin HER2+ breast cancer Leptomeningeal disease 

Notes

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726.  https://doi.org/10.1200/JCO.2002.20.3.719 CrossRefPubMedGoogle Scholar
  2. 2.
    Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977.  https://doi.org/10.1002/cncr.11436 CrossRefPubMedGoogle Scholar
  3. 3.
    Witzel I, Oliveira-Ferrer L, Pantel K, Muller V, Wikman H (2016) Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res 18:8.  https://doi.org/10.1186/s13058-015-0665-1 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Scott BJ, Oberheim-Bush NA, Kesari S (2016) Leptomeningeal metastasis in breast cancer—a systematic review. Oncotarget 7:3740–3747.  https://doi.org/10.18632/oncotarget.5911 PubMedGoogle Scholar
  5. 5.
    Le Rhun E, Taillibert S, Zairi F, Kotecki N, Devos P, Mailliez A, Servent V, Vanlemmens L, Vennin P, Boulanger T, Baranzelli MC, Andre C, Marliot G, Cazin JL, Dubois F, Assaker R, Bonneterre J, Chamberlain MC (2013) A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neurooncol 113:83–92.  https://doi.org/10.1007/s11060-013-1092-8 CrossRefPubMedGoogle Scholar
  6. 6.
    Mittica G, Senetta R, Richiardi L, Ruda R, Coda R, Castellano I, Sapino A, Cassoni P (2015) Meningeal carcinomatosis underdiagnosis and overestimation: incidence in a large consecutive and unselected population of breast cancer patients. BMC Cancer 15:1021.  https://doi.org/10.1186/s12885-015-2042-y CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bousquet G, Darrouzain F, de Bazelaire C, Ternant D, Barranger E, Winterman S, Madelaine-Chambin I, Thiebaut JB, Polivka M, Paintaud G, Culine S, Janin A (2016) Intrathecal trastuzumab halts progression of CNS metastases in breast cancer. J Clin Oncol 34:e151–e155.  https://doi.org/10.1200/JCO.2012.44.8894 CrossRefPubMedGoogle Scholar
  8. 8.
    Lu NT, Raizer J, Gabor EP, Liu NM, Vu JQ, Slamon DJ, Barstis JL (2015) Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient. J Immunother Cancer 3:41.  https://doi.org/10.1186/s40425-015-0084-y CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F (2008) High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 19:1978–1980.  https://doi.org/10.1093/annonc/mdn654 CrossRefPubMedGoogle Scholar
  10. 10.
    Park WY, Kim HJ, Kim K, Bae SB, Lee N, Lee KT, Won JH, Park HS, Lee SC (2016) Intrathecal trastuzumab treatment in patients with breast cancer and leptomeningeal carcinomatosis. Cancer Res Treat 48:843–847.  https://doi.org/10.4143/crt.2014.234 CrossRefPubMedGoogle Scholar
  11. 11.
    Stemmler HJ, Schmitt M, Harbeck N, Willems A, Bernhard H, Lassig D, Schoenberg S, Heinemann V (2006) Application of intrathecal trastuzumab (herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 15:1373–1377PubMedGoogle Scholar
  12. 12.
    Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, Dimopoulos MA, Preusser M (2013) Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat 139:13–22.  https://doi.org/10.1007/s10549-013-2525-y CrossRefPubMedGoogle Scholar
  13. 13.
    Scott BJ, Kesari S (2013) Leptomeningeal metastases in breast cancer. Am J Cancer Res 3:117–126PubMedPubMedCentralGoogle Scholar
  14. 14.
    Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V (2007) Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 18:23–28.  https://doi.org/10.1097/01.cad.0000236313.50833.ee CrossRefPubMedGoogle Scholar
  15. 15.
    Cao Y, Tsien CI, Shen Z, Tatro DS, Ten Haken R, Kessler ML, Chenevert TL, Lawrence TS (2005) Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 23:4127–4136.  https://doi.org/10.1200/JCO.2005.07.144 CrossRefPubMedGoogle Scholar
  16. 16.
    Mego M, Sycova-Mila Z, Obertova J, Rajec J, Liskova S, Palacka P, Porsok S, Mardiak J (2011) Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis. Breast 20:478–480.  https://doi.org/10.1016/j.breast.2011.05.007 CrossRefPubMedGoogle Scholar
  17. 17.
    Stemmler HJ, Mengele K, Schmitt M, Harbeck N, Laessig D, Herrmann KA, Schaffer P, Heinemann V (2008) Intrathecal trastuzumab (herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs 19:832–836.  https://doi.org/10.1097/CAD.0b013e32830b58b0 CrossRefPubMedGoogle Scholar
  18. 18.
    Chamberlain M, Junck L, Brandsma D, Soffietti R, Ruda R, Raizer J, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Walker J, van den Bent M, Wen PY, Jaeckle KA (2017) Leptomeningeal metastases: a RANO proposal for response criteria. Neuro-Oncology 19:484–492.  https://doi.org/10.1093/neuonc/now183 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Nicholas B. Figura
    • 1
  • Wendy Long
    • 2
  • Michael Yu
    • 1
  • Timothy J. Robinson
    • 1
  • Sepideh Mokhtari
    • 2
  • Arnold B. Etame
    • 2
  • Nam D. Tran
    • 2
  • Roberto Diaz
    • 1
  • Hatem Soliman
    • 3
  • Heather S. Han
    • 3
  • Solmaz Sahebjam
    • 2
  • Peter A. Forsyth
    • 2
  • Kamran A. Ahmed
    • 1
  1. 1.Department of Radiation OncologyH. Lee Moffitt Cancer Center and Research InstituteTampaUSA
  2. 2.Department of Neuro OncologyH. Lee Moffitt Cancer Center and Research InstituteTampaUSA
  3. 3.Department of Breast OncologyH. Lee Moffitt Cancer Center and Research InstituteTampaUSA

Personalised recommendations